MAPT and tauopathy: In 5xFAD mice (a model of AD in which Aβ is overexpressed), ibrutinib suppressed Aβ and tau pathology and neuroinflammation, and in PS19 mice (a tauopathy model), ibrutinib significantly alleviated tau phosphorylation and tau‐evoked neuroinflammation.